Gene editing trial starts
RecordSTO-0TX3ETZCNN-WAE7M6EGY6-X5NSGD
China · 2024
Gene editing trial starts in China were 17 in 2024 (ClinicalTrials.gov).
- Publisher
- ClinicalTrials.gov
- Authority tier
- T1 Official
- Locator
- totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China.
- Retrieved
- 27 Sep 2026
- Status
- Verified
What the source says
{"totalCount":17,"studies":[
Checked: the figure 17 is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
ClinicalTrials.gov (U.S. National Library of Medicine). (2024). ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_0TX3ETZCNNWAE7M6EGY6X5NSGD
Other formats: MLA, Chicago, BibTeX
- MLA
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China." 2024, https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_0TX3ETZCNNWAE7M6EGY6X5NSGD.
- Chicago
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China." 2024. https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_0TX3ETZCNNWAE7M6EGY6X5NSGD.
- BibTeX
- @misc{clinicaltrialsgo2024ctgovx5nsgd, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_0TX3ETZCNNWAE7M6EGY6X5NSGD}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR\%20OR\%20Cas9\%20OR\%20Cas12\%20OR\%20\%22base\%20editing\%22\%20OR\%20\%22base\%20editor\%22\%20OR\%20\%22prime\%20editing\%22\%20OR\%20\%22gene\%20editing\%22\%20OR\%20\%22genome\%20editing\%22\%20OR\%20\%22zinc\%20finger\%20nuclease\%22\%20OR\%20TALEN\%20OR\%20exagamglogene\%20OR\%20NTLA-2001\%20OR\%20NTLA-2002\%20OR\%20nexiguran\%20OR\%20lonvoguran\%20OR\%20VERVE-101\%20OR\%20VERVE-102\%20OR\%20BEAM-101\%20OR\%20BEAM-302\%20OR\%20EBT-101\%20OR\%20EDIT-101\%20OR\%20CTX310\%20OR\%20\%22epigenetic\%20editing\%22\%20OR\%20CTX320\%20OR\%20YOLT-101\%20OR\%20YOLT-201\%20OR\%20ART001\%20OR\%20CS-101\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2024-01-01\%2C2024-12-31\%5D\%20AND\%20AREA\%5BLocationCountry\%5D\%22China\%22\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China
- Type
- Dataset
- Published
- —
- Locator
- totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China.
- Retrieved
- 27 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- Public domain
Verification
- Status
- Verified
- Review protocol
- pipeline:ctgov-api-totalcount-verified
- Checked on
- 27 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_0TX3ETZCNNWAE7M6EGY6X5NSGD